

## Japan-based Fujirebio acquires ADx Neurosciences for €40 M

24 June 2022 | News

**To bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry**



Japan's H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and Belgium-based ADx NeuroSciences NV have announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending the satisfaction of customary closing conditions, the deal is expected to close in July 2022. ADx NeuroSciences becomes a wholly owned subsidiary of Fujirebio Europe NV.

ADx NeuroSciences specializes in generating tailor-made antibodies and developing assays for pharma and *in vitro* diagnostics (IVD) companies. As part of Fujirebio, ADx NeuroSciences will continue to serve its current partners and customers in their diagnostic biomarker development and will continue to expand its extensive portfolio of state-of-the-art biomarkers and antibodies to help detect neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Its current pipeline encompasses, next to several phospho-tau specific antibodies for measurement in plasma, biomarkers targeting synaptic degeneration supporting prognosis of these devastating diseases.

Fujirebio is a trusted partner for high-quality IVD testing solutions and a historical pioneer in neurodegenerative disease diagnostics. The company will combine the unique know-how and biomarker portfolio of ADx NeuroSciences with both its own solid experience in bringing high quality IVD products to the market and its strategic CDMO partnerships that make unique testing solutions available to the entire diagnostics industry. The acquisition also concentrates considerable additional know-how, expertise, and resources in the Fujirebio Neuro Center of Excellence.